GSK/Pozen Trexima update
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pozen plans to submit an NDA in the third quarter for its migraine combination therapy Trexima (sumatriptan/naproxen) following a pre-NDA meeting with FDA. The firm also announced that Trexima showed statistically significant results for all primary endpoints in a second pivotal trial. Based on discussion at the pre-NDA meeting, Pozen "believes that no additional preclinical or clinical trials are necessary for submission," the firm says April 21. In the pivotal trial, Trexima showed superiority over its individual components with respect to pain-free response and pain relief. At the moment, Trexima appears to be Pozen's most promising product. The firm's other migraine agents, MT-100 and MT-300, are both "not approvable" at FDA. The agency recently postponed an MT-100 advisory committee...
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.